Fluvoxamine Maleate NDC 27241-275

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-275Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0275Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-275-30	27241027530	30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (27241-275-30)Marketed from Oct 17, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fluvoxamine Maleate
Generic name (nonproprietary): fluvoxamine maleate
Active ingredients: Fluvoxamine maleate — 150 mg/1
Dosage form: Capsule, Extended release
Route: Oral
Labeler: Ajanta Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219055
Marketing start: Oct 17, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Serotonin Uptake Inhibitors (Mechanism)
Identifiers: Product ID 27241-275_658eeffd-e919-4d41-8814-e55273a471e9SPL ID 658eeffd-e919-4d41-8814-e55273a471e9SPL set ID 0a6836ab-bd0e-410b-82af-07720e386532RxCUI 903873, 903879UNII 5LGN83G74VUPC 0327241275302, 0327241274305
Pharmacologic class: Serotonin Reuptake Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241027530 followed by a unit qualifier and the quantity

Package 27241-0275-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 4, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Fluvoxamine maleate extended-release capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD) ( 1 ). Efficacy was demonstrated in: One 12-week study fluvoxamine maleate extended-release capsules in adults ( 14.1 ). Two 10-week studies with immediate-release (IR) fluvoxamine tablets in adults and one 10-week study with IR fluvoxamine tablets in children and adolescents ( 14.1 , 14.3 ). One maintenance study with IR fluvoxamine tablets ( 14.2 ). 1.1 Obsessive Compulsive Disorder Fluvoxamine maleate extended-release capsules are indicated for the treatment of obsessive compulsive disorder (OCD), as defined in the DSM-IV. Obse…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 219055

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219055
Product	Strength	Form · route	Labeler	Product NDC
Fluvoxamine Maleate	Fluvoxamine maleate 100 mg/1	Capsule, Extended releaseOral	Ajanta Pharma USA Inc.	27241-274